Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle ...

snapping up 2seventy bio’s R&D unit at the beginning of 2024 and buying Decibel Therapeutics, a biotech developing gene therapies for hearing loss, the year before that.

Regeneron acquired DB-OTO as part of its $109 million acquisition of Decibel Therapeutics last year. Meanwhile, French biotech Sensorion is running a phase 1/2 trial of its SENS-501 (OTOF-GT ...

Elicera Therapeutics AB (publ)'s Revenue of 378.977 K ranks in the 13.1% percentile for the Sector. The following table provides additional summary stats: ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

JW Therapeutics's latest twelve months p/e ratio is -0.8x JW Therapeutics's p/e ratio increased in 2021 (-4.4x, -34.5%), 2022 (-1.8x, -58.4%), and 2023 (-1.1x, -41.9%). We've identified the ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused ...

Too few leaders have learned the critical lesson that international cooperation is essential to pandemic prevention, ...

Neurotech Reports, the longest-serving publishing and market intelligence firm covering the neuromodulation industry, announced the launch of its first European management ...

Health-care companies slipped, as traders rotated back into sectors more associated with artificial-intelligence developments. Novo Nordisk said the Food and Drug Administration approved the ...

The United States was once the global leader in science and technology, but now other countries, notably China, are catching ...